Korean J Gastroenterol.  2024 Nov;84(5):195-200. 10.4166/kjg.2024.123.

Serological Markers to Assess Liver Fibrosis and Their Roles

• Kim BK

• KMID: 2561588
• DOI: http://doi.org/10.4166/kjg.2024.123

Abstract

Chronic liver disease is a significant public health issue worldwide, with the degree of liver fibrosis and its progression significantly influencing the treatment and prognosis. A liver biopsy is the standard diagnostic method, but it is invasive and presents various issues. Therefore, numerous non-invasive diagnostic methods have been developed. Serum markers are categorized into indirect markers, which reflect liver damage, inflammation, or functional changes, and direct markers, which measure the components released into the bloodstream during fibrosis. In addition, various kinds of formulas that combined direct/indirect markers and demographic variables were developed and validated with encouraging outcomes. Nevertheless, despite their convenience, serum indicators require cautious interpretation because they are affected by a number of factors. More research will be needed to determine if the clinical course of chronic liver disease under a disease-specific treatment could be monitored appropriately using serological markers.

Keyword

Non-invasive; Diagnosis; Liver; Fibrosis; Serology

Reference

1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. 2009; Liver biopsy. Hepatology. 49:1017–1044. DOI: 10.1002/hep.22742. PMID: 19243014.

2. Rosenberg WM, Voelker M, Thiel R, et al. 2004; Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 127:1704–1713. DOI: 10.1053/j.gastro.2004.08.052. PMID: 15578508.

3. Kim MN, Han JW, An J, et al. 2024; KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease. Clin Mol Hepatol. 30(Suppl):S5–S105. DOI: 10.3350/cmh.2024.0506. PMID: 39159947. PMCID: PMC11493350.

4. Anstee QM, Castera L, Loomba R. 2022; Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol. 76:1362–1378. DOI: 10.1016/j.jhep.2022.03.026. PMID: 35589256.

5. Lee Y, Bae S, Kim JH, et al. 2023; Diagnostic efficacy of serum asialo α1-acid glycoprotein levels for advanced liver fibrosis and cirrhosis in patients with chronic hepatitis B compared to that in healthy subjects: A prospective study. J Clin Med. 12:712. DOI: 10.3390/jcm12020712. PMID: 36675640. PMCID: PMC9863335.

6. Lee EY, Kang JH, Kim KA, et al. 2006; Development of a rapid, immunochromatographic strip test for serum asialo alpha1-acid glycoprotein in patients with hepatic disease. J Immunol Methods. 308:116–123. DOI: 10.1016/j.jim.2005.10.010. PMID: 16403512.

7. Sheth SG, Flamm SL, Gordon FD, Chopra S. 1998; AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 93:44–48. DOI: 10.1111/j.1572-0241.1998.044_c.x. PMID: 9448172.

8. Williams AL, Hoofnagle JH. 1988; Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 95:734–739. DOI: 10.1016/S0016-5085(88)80022-2. PMID: 3135226.

9. Wai CT, Greenson JK, Fontana RJ, et al. 2003; A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 38:518–526. DOI: 10.1053/jhep.2003.50346. PMID: 12883497.

10. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. 2008; Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 57:1441–1447. DOI: 10.1136/gut.2007.146019. PMID: 18390575.

11. Sterling RK, Lissen E, Clumeck N, et al. 2006; Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 43:1317–1325. DOI: 10.1002/hep.21178. PMID: 16729309.

12. Forns X, Ampurdanès S, Llovet JM, et al. 2002; Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 36:986–992. DOI: 10.1053/jhep.2002.36128. PMID: 12297848.

13. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. 2010; Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 59:1265–1269. DOI: 10.1136/gut.2010.216077. PMID: 20801772.

14. Imperiale TF, Said AT, Cummings OW, Born LJ. 2000; Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol. 95:2328–2332. DOI: 10.1111/j.1572-0241.2000.02322.x. PMID: 11007237.

15. Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. 2009; Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol. 8:26–31. DOI: 10.1016/S1665-2681(19)31807-1. PMID: 19221530.

16. Calès P, Lainé F, Boursier J, et al. 2009; Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 50:165–173. DOI: 10.1016/j.jhep.2008.07.035. PMID: 18977552.

17. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. 2008; AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 7:350–357. DOI: 10.1016/S1665-2681(19)31836-8. PMID: 19034235.

18. Angulo P, Hui JM, Marchesini G, et al. 2007; The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 45:846–854. DOI: 10.1002/hep.21496. PMID: 17393509.

19. Narimatsu H. 2015; Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev Proteomics. 12:683–693. DOI: 10.1586/14789450.2015.1084874. PMID: 26394846.

20. Harrison SA, Ratziu V, Boursier J, et al. 2020; A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 5:970–985. DOI: 10.1016/S2468-1253(20)30252-1. PMID: 32763196.

21. Shirabe K, Bekki Y, Gantumur D, et al. 2018; Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol. 53:819–826. DOI: 10.1007/s00535-017-1425-z. PMID: 29318378.

22. Daniels SJ, Leeming DJ, Eslam M, et al. 2019; ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 69:1075–1086. DOI: 10.1002/hep.30163. PMID: 30014517.

23. Boyle M, Tiniakos D, Schattenberg JM, et al. 2019; Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep. 1:188–198. DOI: 10.1016/j.jhepr.2019.06.004. PMID: 32039369. PMCID: PMC7001575.

24. Guha IN, Parkes J, Roderick P, et al. 2008; Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 47:455–460. DOI: 10.1002/hep.21984. PMID: 18038452.

25. Ratziu V, Massard J, Charlotte F, et al. 2006; Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 6:6. DOI: 10.1186/1471-230X-6-6. PMID: 16503961. PMCID: PMC1386692.

26. Harrison SA, Ratziu V, Magnanensi J, et al. 2023; NIS2+™, an optimisation of the blood-based biomarker NIS4^® technology for the detection of at-risk NASH: A prospective derivation and validation study. J Hepatol. 79:758–767. DOI: 10.1016/j.jhep.2023.04.031. PMID: 37224923.

27. Munteanu M, Tiniakos D, Anstee Q, et al. 2016; Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 44:877–889. DOI: 10.1111/apt.13770. PMID: 27549244. PMCID: PMC5113673.

28. Xiao G, Yang J, Yan L. 2015; Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 61:292–302. DOI: 10.1002/hep.27382. PMID: 25132233.

29. Sebastiani G, Castera L, Halfon P, et al. 2011; The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 34:1202–1216. DOI: 10.1111/j.1365-2036.2011.04861.x. PMID: 21981787.

30. Zhu X, Wang LC, Chen EQ, et al. 2011; Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci. 56:2742–2749. DOI: 10.1007/s10620-011-1659-1. PMID: 21399926.

31. Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. 2012; Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 12:14. DOI: 10.1186/1471-230X-12-14. PMID: 22333407. PMCID: PMC3306191.

32. Kim BK, Kim SU, Kim HS, et al. 2012; Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 7:e35825. DOI: 10.1371/journal.pone.0035825. PMID: 22536445. PMCID: PMC3335013.

33. Salkic NN, Jovanovic P, Hauser G, Brcic M. 2014; FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol. 109:796–809. DOI: 10.1038/ajg.2014.21. PMID: 24535095.

34. Feng S, Wang Z, Zhao Y, Tao C. 2020; Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis. Sci Rep. 10:10582. DOI: 10.1038/s41598-020-67471-y. PMID: 32601332. PMCID: PMC7324360.

35. Vallet-Pichard A, Mallet V, Nalpas B, et al. 2007; FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 46:32–36. DOI: 10.1002/hep.21669. PMID: 17567829.

36. Joo SK, Kim JH, Oh S, et al. 2015; Prospective comparison of noninvasive fibrosis assessment to predict advanced fibrosis or cirrhosis in Asian patients with hepatitis C. J Clin Gastroenterol. 49:697–704. DOI: 10.1097/MCG.0000000000000215. PMID: 25203365.

37. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. 2016; Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther. 43:16–29. DOI: 10.1111/apt.13446. PMID: 26516104. PMCID: PMC4737301.

38. Crossan C, Tsochatzis EA, Longworth L, et al. 2015; Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 19:1–409. DOI: 10.3310/hta19090. PMID: 25633908. PMCID: PMC4781028.

39. Paggi S, Colli A, Fraquelli M, et al. 2008; A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation. J Hepatol. 49:564–571. DOI: 10.1016/j.jhep.2008.07.007. PMID: 18706734.

40. Lin ZH, Xin YN, Dong QJ, et al. 2011; Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 53:726–736. DOI: 10.1002/hep.24105. PMID: 21319189.

41. Martinez SM, Fernández-Varo G, González P, et al. 2011; Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 33:138–148. DOI: 10.1111/j.1365-2036.2010.04500.x. PMID: 21083589.

42. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. 2013; The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 59:236–242. DOI: 10.1016/j.jhep.2013.03.016. PMID: 23523583.

43. Sharma C, Cococcia S, Ellis N, Parkes J, Rosenberg W. 2021; Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. J Gastroenterol Hepatol. 36:1788–1802. DOI: 10.1111/jgh.15482. PMID: 33668077.

44. Imbert-Bismut F, Ratziu V, Pieroni L, et al. 2001; Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 357:1069–1075. DOI: 10.1016/S0140-6736(00)04258-6. PMID: 11297957.

45. Han S, Choi M, Lee B, et al. 2022; Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gut Liver. 16:952–963. DOI: 10.5009/gnl210391. PMID: 35193993. PMCID: PMC9668505.

46. Mózes FE, Lee JA, Selvaraj EA, et al. 2022; Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 71:1006–1019. DOI: 10.1136/gutjnl-2021-324243. PMID: 34001645. PMCID: PMC8995830.

47. Jun DW, Kim SG, Park SH, et al. 2017; External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients. J Gastroenterol Hepatol. 32:1094–1099. DOI: 10.1111/jgh.13648. PMID: 27859583.

48. Pimentel SK, Strobel R, Gonçalves CG, Sakamoto DG, Ivano FH, Coelho JC. 2010; Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery. Arq Gastroenterol. 47:170–173. DOI: 10.1590/S0004-28032010000200010. PMID: 20721462.

49. Sumida Y, Yoneda M, Hyogo H, et al. 2011; A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 46:257–268. DOI: 10.1007/s00535-010-0305-6. PMID: 20842510.

50. Wong VW, Vergniol J, Wong GL, et al. 2010; Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 51:454–462. DOI: 10.1002/hep.23312. PMID: 20101745.

51. Ruffillo G, Fassio E, Alvarez E, et al. 2011; Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 54:160–163. DOI: 10.1016/j.jhep.2010.06.028. PMID: 20934232.

52. Musso G, Gambino R, Cassader M, Pagano G. 2011; Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 43:617–649. DOI: 10.3109/07853890.2010.518623. PMID: 21039302.

53. Qureshi K, Clements RH, Abrams GA. 2008; The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD. Obes Surg. 18:264–270. DOI: 10.1007/s11695-007-9295-8. PMID: 18214632.

54. Wong VW, Wong GL, Chim AM, et al. 2008; Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 103:1682–1688. DOI: 10.1111/j.1572-0241.2008.01933.x. PMID: 18616651.

55. Vali Y, Lee J, Boursier J, et al. 2020; Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 73:252–262. DOI: 10.1016/j.jhep.2020.03.036. PMID: 32275982.

56. Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. 2018; Accuracy of the Enhanced Liver Fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology. 154:1369–1379. DOI: 10.1053/j.gastro.2018.01.005. PMID: 29317276.

57. Connoley D, Patel PJ, Hogan B, et al. 2021; The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study. BMC Gastroenterol. 21:268. DOI: 10.1186/s12876-021-01795-5. PMID: 34182924. PMCID: PMC8240375.

58. Madsen BS, Thiele M, Detlefsen S, et al. 2020; Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4. Liver Int. 40:1701–1712. DOI: 10.1111/liv.14491. PMID: 32339377. PMCID: PMC7383987.

59. Sharma S, Khalili K, Nguyen GC. 2014; Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol. 20:16820–16830. DOI: 10.3748/wjg.v20.i45.16820. PMID: 25492996. PMCID: PMC4258552.

60. Tatler AL. 2019; Recent advances in the non-invasive assessment of fibrosis using biomarkers. Curr Opin Pharmacol. 49:110–115. DOI: 10.1016/j.coph.2019.09.010. PMID: 31756570.

61. McPherson S, Hardy T, Dufour JF, et al. 2017; Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 112:740–751. DOI: 10.1038/ajg.2016.453. PMID: 27725647. PMCID: PMC5418560.

62. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. 2008; Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis. 17:187–191.